Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
Top Page
Prescient Therapeutics Limited
(Sydney:PTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.05
▼(-36.25% Downside)
Action:ReiteratedDate:03/10/26
The score is primarily held back by weak financial quality—ongoing losses and persistent negative free cash flow—despite strong revenue growth and low leverage. Technical signals are also soft (below key moving averages and negative MACD), while valuation is difficult to support given a negative P/E and no dividend yield provided.
Positive Factors
Strong revenue growth
Sustained ~44% revenue growth indicates meaningful commercial traction and expanding market adoption for the company’s oncology programs. Over a 2–6 month horizon this trend supports scale benefits, higher absolute gross profit, and stronger negotiating leverage with partners and funders as programs advance.
Negative Factors
Persistent negative cash flow
Chronic negative operating and free cash flow denotes a cash-consuming biotech model that will remain dependent on external funding. Over 2–6 months, elevated cash burn increases dilution risk, pressures program funding, and limits ability to self-fund trials or scale commercial initiatives absent material financing or partnership.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained ~44% revenue growth indicates meaningful commercial traction and expanding market adoption for the company’s oncology programs. Over a 2–6 month horizon this trend supports scale benefits, higher absolute gross profit, and stronger negotiating leverage with partners and funders as programs advance.
Read all positive factors
Prescient Therapeutics Limited (PTX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$55.73M
Dividend YieldN/A
Average Volume (3M)690.15K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth10.78%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prescient Therapeutics Limited Business Overview & Revenue Model
Company Description
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Pha...
How the Company Makes Money
null...
Prescient Therapeutics Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.11M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| Gross Profit | 3.11M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| EBITDA | -10.06M | -7.54M | -7.19M | -7.46M | -6.86M | -5.32M |
| Net Income | -8.86M | -7.32M | -8.24M | -7.00M | -5.12M | -4.15M |
Balance Sheet | ||||||
| Total Assets | 18.48M | 14.56M | 20.39M | 28.11M | 17.62M | 20.97M |
| Cash, Cash Equivalents and Short-Term Investments | 9.77M | 6.93M | 14.51M | 21.92M | 12.28M | 16.12M |
| Total Debt | 495.89K | 0.00 | 330.49K | 0.00 | 0.00 | 165.83K |
| Total Liabilities | 1.51M | 3.17M | 2.33M | 2.03M | 856.01K | 539.68K |
| Stockholders Equity | 16.97M | 11.39M | 18.07M | 26.08M | 16.76M | 20.43M |
Cash Flow | ||||||
| Free Cash Flow | -8.00M | -7.24M | -7.40M | -6.19M | -4.32M | -3.97M |
| Operating Cash Flow | -8.00M | -7.24M | -7.40M | -6.19M | -4.31M | -3.97M |
| Investing Cash Flow | 2.00M | 4.00M | 12.00M | -16.00M | -4.43K | -2.31K |
| Financing Cash Flow | 9.02M | -330.49K | 18.15K | 15.83M | 428.29K | 12.75M |
Prescient Therapeutics Limited Technical Analysis
Negative
0.08
Price Trends
0.07
Negative
0.07
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
40.33
Neutral
2.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PTX, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 2.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PTX.
Prescient Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$71.24M | -7.57 | -179.37% | ― | ― | 16.61% | |
53 Neutral | AU$34.90M | -2.50 | -258.19% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$195.26M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$85.71M | -14.80 | -40.65% | ― | 700.00% | 26.88% |
* Healthcare Sector Average
AU:PTX
Prescient Therapeutics Limited
0.05
0.01
23.26%
AU:CYP
Cynata Therapeutics Limited
0.30
0.11
56.25%
AU:SPL
Starpharma Holdings Limited
0.47
0.37
374.49%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:ALA
Arovella Therapeutics Limited
0.07
-0.02
-19.32%
Prescient Therapeutics Limited Corporate Events
Prescient Tightens Governance With Updated Securities Trading Policy
Feb 25, 2026
Prescient Therapeutics Limited has updated and reapproved its Securities Trading Policy, which governs how directors, officers, employees, consultants, contractors and their closely related parties may deal in the company’s securities. The p...
Prescient widens half-year loss as R&D spend climbs but bolsters balance sheet
Feb 24, 2026
Prescient Therapeutics reported a half-year loss after tax of $3.99 million for the period ended 31 December 2025, a 62.8% increase on the prior corresponding period, as revenues from ordinary activities fell to $3,712. The result reflects higher ...
Prescient Wins EU Orphan Status for PTX‑100, Advances Global CTCL Trial and Cell Therapy Platforms
Jan 30, 2026
Prescient Therapeutics reported steady progress in the December 2025 quarter, highlighted by the European Medicines Agency granting Orphan Drug Designation for PTX‑100 in cutaneous T‑cell lymphoma and European authorisation to commence...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.